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ABSTRACT
Background The main aim was to examine age- specific 
risk factor associations with incident atrial fibrillation (AF) 
and their attributable fraction in a large European cohort. 
Additionally, we aimed to examine risk of stroke and 
mortality in relation to new- onset AF across age.
Methods We used individual- level data (n=66 951, 
49.1% men, age range 40–98 years at baseline) from 
five European cohorts of the MOnica Risk, Genetics, 
Archiving and Monograph Consortium. The participants 
were followed for incident AF for up to 10 years and the 
association with modifiable risk factors from the baseline 
examinations (body mass index (BMI), hypertension, 
diabetes, daily smoking, alcohol consumption and history 
of stroke and myocardial infarction (MI)) was examined. 
Additionally, the participants were followed up for incident 
stroke and all- cause mortality after new- onset AF.
Results AF incidence increased from 0.9 per 1000 
person- years at baseline age 40–49 years, to 17.7 at 
baseline age ≥70 years. Multivariable- adjusted Cox 
models showed that higher BMI, hypertension, high 
alcohol consumption and a history of stroke or MI were 
associated with increased risk of AF across age groups 
(p<0.05). Between 30% and 40% of the AF risk could be 
attributed to BMI, hypertension and a history of stroke or 
MI. New- onset AF was associated with a twofold increase 
in risk of stroke and death at ages≥70 years (p≤0.001).
Conclusion In this large European cohort aged 40 years 
and above, risk of AF was largely attributed to BMI, high 
alcohol consumption and a history MI or stroke from 
middle age. Thus, preventive measures for AF should 
target risk factors such as obesity and hypertension from 
early age and continue throughout life.
INTRODUCTION
Atrial fibrillation (AF) has become a disease 
with significant public health impact, esti-
mated to affect 20 million men and 12 million 
women worldwide.1 Major complications 
of AF include stroke,2 hospitalisations3 
and mortality.4 Several predictors for AF 
have been described, including modifiable 
risk factors such as obesity, hypertension, 
diabetes, smoking and previous cardiovas-
cular disease,5–7 which may together account 
for more than 50% of the AF burden.8 
Key questions
What is already known about this subject?
 ► Modifiable risk factors for atrial fibrillation (AF), such 
as obesity, hypertension, diabetes, smoking and 
previous cardiovascular disease, may together ac-
count for more than 50% of the AF burden. However, 
although risk factors for AF have been extensively 
examined, limited attention has been devoted to 
their attributable fraction in relation to age.
What does this study add?
 ► In this large cohort of adult and elderly European 
men and women, risk of AF was primarily attribut-
ed to body mass index, hypertension and previous 
stroke or myocardial infarction, together explaining 
30%–40% of the AF risk. Population attributable 
risk varied with age, with a substantial AF burden 
attributed to body mass index at ages 40–69 years, 
whereas population attributable risk for hyperten-
sion was highest and significant only at ages ≥60 
years. The AF risk attributed to previous myocardial 
infarction or stroke increased slightly with age.
How might this impact on clinical practice?
 ► Increased understanding of the relative contribution 
of modifiable risk factors to the development of AF, 
as well as complications of AF across age groups, 
would help target prevention and allocate health-
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AF incidence increases with age9–11 and is commonly 
related to the presence of cardiovascular risk factors or 
disease in older individuals.12 On the other hand, tran-
sition to unhealthy metabolic risk factor constellations 
occurs earlier in life,13 and a recent study suggests that 
even in early- onset AF, 90% of individuals had metabolic 
risk factors and comorbidities.14 Although several large 
cohort studies have addressed the role of lifestyle risk 
factor for AF15 16 and potential sex differences,17 there is 
a lack of research on the impact of the risk factors in rela-
tion to age at AF onset.
Increased understanding of the contribution of modi-
fiable risk factors in relation to age at AF onset, as well as 
complications of AF across age groups, would help target 
prevention and allocate healthcare resources specific to 
age group needs. The MOnica Risk, Genetics, Archiving 
and Monograph (MORGAM) consortium provides a 
unique opportunity to expand the understanding of AF 
risk factors and complications from middle aged to older 
individuals. The main aim of this study was to examine 
age- specific risk factor associations with incident AF and 
their attributable fraction in European adults and elderly. 
Furthermore, we aimed to examine the risk of stroke and 
all- cause mortality after new- onset AF at different ages.
METHODS
Study population
This study is based on the MORGAM consortium, which 
is a multinational collaborative initiative addressing cardi-
ovascular biomarkers, risk factors and endpoints using 
pooled and harmonised data from European community- 
based cohorts.18 In this study, individual- level data from 
five cohort studies in the MORGAM consortium18; DAN- 
MONICA (Denmark),19 FINRISK (Finland)20 Moli- sani 
(Italy),21 Northern Sweden MONICA,22 and the Tromsø 
Study (Norway)23 were included. Cohort- specific proce-
dures for enrolment and follow- up are provided in the 
online supplemental D1. In brief, all included cohort 
studies are population- based with repeated surveys. The 
studies included in MORGAM are population- based 
studies covering a specific region in several European 
countries, recruiting from birth cohorts or random 
sampling from a national or local population register. 
Most studies do not specify exclusion criteria.
In total, 66 951 individuals from the five MORGAM 
cohort studies were included in our analyses, after exclu-
sion due to left censoring (n=448), prevalent AF at base-
line (n=879) and/or missing baseline AF information 
(n=6757). Only individuals aged ≥40 years at baseline 
were included in order to harmonise the age range.
Risk factors and biomarkers
Data on risk factors were available from the baseline 
examinations, which were conducted between 1982 
and 2010. Systolic blood pressure (SBP), total choles-
terol, weight and height were measured by standard-
ised methods and body mass index (BMI) (kg/m2) 
was calculated. Information on daily smoking, average 
alcohol consumption, diabetes, antihypertensive medi-
cation, history of stroke and myocardial infarction (MI) 
was self- reported. Harmonised data from the various 
studies were transferred to the MORGAM Data Centre 
in Helsinki.24
Biomarkers were available for 39%–49% of the partici-
pants (available in FINRISK, Moli- sani, Northern Sweden, 
and Dan- MONICA) (online supplemental tables S1–
S5). Measurements from stored blood samples include 
C reactive protein (CRP) (n=32 893), which was deter-
mined by latex immunoassay CRP16 (Abbott, Architect 
c8000), and N- terminal- pro B- type natriuretic peptide 
(Nt- pro- BNP) (n=26 048, measured on the ELECSYS 
2010 platform using an electrochemiluminescence 
immunoassay (Roche Diagnostics). Analyses of estimated 
glomerular filtration rate (eGFR), CRP, and Nt- proBNP 
are described in detail elsewhere.25
Follow-up for AF, stroke and mortality
Incident AF, non- fatal and fatal stroke events, and death 
during follow- up were identified by linkage to regional 
or national hospital discharge registries, diagnosis regis-
tries, and causes of death registries, which were also 
screened for incident AF as a comorbidity of individuals 
who died of other causes. Follow- up lasted from the date 
of the baseline examinations to the end of 2010 (DAN- 
MONICA, Tromsø and FINRISK) or 2011 (Moli- sani and 
Northern Sweden), truncated at 10 years for the data 
analysis (median (IQR): 10.0 (4.8–10.0) years).
Statistical analyses
For each age group (40–49, 50–59, 60–69 and ≥70 years 
at baseline), AF incidence rates were calculated as the 
number of AF cases per 1000 person- years within the 
10- year follow- up period. The association between risk 
factors and incident AF within each age stratum was 
estimated as HR with 95% CI using Cox regression. 
The goodness- of- fit of all Cox models was checked with 
respect to the proportional hazard (PH) assumption. 
In order to assure that the PH assumption was valid 
during the Cox regressions, interactions with time were 
adjusted for when needed. The PH assumptions were 
tested using the Schoenfeld residuals. Prevalent AF cases 
were excluded from the analysis. Multivariable- adjusted 
models include adjustment for age, sex, BMI, hyper-
tension (SBP ≥140 mm Hg and/or taking antihyperten-
sive drugs), total serum cholesterol, smoking, history of 
diabetes, alcohol consumption and study site. We set the 
follow- up duration to a fixed maximum value (10 years) 
to avoid large differences in follow- up. Missing data were 
handled by using available cases.
Population attributable fraction (PAF) was calculated 
for each categorical risk factor. In each age group, the 
PAF for a risk factor was estimated using the fully adjusted 
estimated HRs and the following equation26:
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where PAFi is the PAF of the i- th category, HRi is the fully 
adjusted HR for the i- th category, pdi is the proportion of 
those in the i- th category among the cases during the first 
5 years of the follow- up. The total PAF of a risk factor was 
calculated as the sum of all PAFi over i=1 to n, where n is 
the number of categories of the risk factor in question. 
For each PAFi and PAF, a 95% CI was calculated using 
bootstrapping. Bootstrapping was also used to estimate 
the p values for the differences between PAFs of different 
age groups for the same risk factor. To decide whether 
a difference was significant, a (Bonferroni- corrected) 
alpha level of 0.05/N was used, where N is the number of 
comparisons per risk factor category level (there are four 
age groups, so N is (4×4–4)/2=6, so alpha=0.05/6=0.008).
In online supplemental table S6, second- order interac-
tions between covariates were included if they reached 
significance (taking into account multiple testing). Inter-
actions with time since baseline (included in the analysis 
as a time- varying covariate) were included when needed 
to avoid violations of the PH assumption. The PAF anal-
yses used fully adjusted HRs.
In order to estimate the HRs of new- onset AF for stroke 
and mortality by age- decades, time- dependent multiple 
adjusted Cox regressions were performed in each age 
stratum where incident AF was used to predict time to 
event (where event is (1) stroke and (2) mortality). For 
the stroke analysis, cases with previous stroke history were 
excluded.
Analyses were performed in R V.3.5.3, in which Cox 
regressions were performed using the survival package. 
We assumed a two- tailed p<0.05 as statistically significant.
RESULTS
The median age at baseline was 53.5 years (IQR 46.4–
61.2), ranging from 40 to 98 years, and 49.1% of the 66 
951 participants were men (table 1). The prevalence of 
previous disease (diabetes and history of MI or stroke) 
was low (<6%), although more than half of the partici-
pants (52.2%) had an SBP ≥140 mm Hg or were taking 
antihypertensive drugs. About one- fourth (26.0%) of 
the participants smoked daily. Study characteristics by 
cohort are shown in online supplemental tables S1–S5. 
Risk factor distributions at baseline were in general more 
favourable at younger age (table 2). Prevalence of hyper-
tension, overweight, diabetes and previous MI or stroke 
increased with age, whereas smoking decreased gradually 
by age, and daily consumption of alcohol showed a stable 
pattern across all age groups.
Over a follow- up time of up to 10.0 years, 2021 (3.0%) 
cases of AF were detected. AF incidence rate increased 
gradually from 0.9 per 1000 person- years at age 40–49 
years to 17.7 at the age of ≥70 years. Adjusted HR for 
AF increased exponentially with age and was 13.5 times 
higher (HR 13.53, 95% CI 10.98 to 16.68) at ages ≥70 
compared with 40–49 years (figure 1).
Age- stratified unadjusted risk of AF for each risk factor 
is shown in online supplemental table S7. Age- stratified 
multivariable- adjusted Cox regression models showed 
that BMI and a history of MI or stroke were consistently 
associated with increased risk of AF in all age groups 
(p<0.001) (table 3), whereas high alcohol consumption, 
total serum cholesterol, and hypertension increased the 
risk of AF only at certain ages. For each 5 kg/m2 increase 
in BMI, risk of AF increased significantly with 37%–41% 
(p≤0.001) at ages 40–69 years. At the age of ≥70 years, 
AF risk was still positively associated with BMI (HR 1.17, 
95% CI 1.06 to 1.29), but the risk was lower than at 
younger ages (difference from ages 40-69: p≤0.033). A 
history of MI or stroke significantly increased the risk of 
AF (p≤0.001 at all ages), with highest HRs at age 40–49 
years (HR 4.60, 95% CI 2.56 to 8.27; p≥0.011 compared 
with other age groups). High alcohol consumption 
significantly increased the risk of AF by 13%–18% at 
ages up to 70 years (p<0.05), but not in participants ≥70 
years. Total serum cholesterol decreased the risk of AF 
by 4%–11%, but significantly only at ages 50–69 years 
(p<0.05), whereas hypertension increased the risk of AF 
by 19%–40%, although significantly only at older ages 
(≥60 years) (p<0.05). Smoking, CRP and eGFR were not 
significantly associated with AF, whereas participants with 
Nt- pro- BNP levels ≥900 pg/mL showed higher AF risk at 
all ages (p≤0.001).
Table 1 Baseline characteristics of the pooled MORGAM 
cohort (n=66 951)
Characteristics
Median (IQR) or 
n (%) Missing values
Age (years) 53.5 (46.4–61.2) 0 (0.0%)
Sex (n (%) men) 32 855 (49.1) 0 (0.0%)
BMI (kg/m2) 26.4 (23.9 to 29.5) 480 (0.7%)
Systolic blood pressure (mm Hg)* 137 (124 to 152) 459 (0.7%)
Total serum cholesterol (mmol/L) 5.9 (5.2 to 6.8) 669 (1.0%)
Daily smoker 17 305 (26.0) 370 (0.6%)
History of diabetes 3526 (5.3) 83 (0.1%)
Taking antihypertensive drugs 11 977 (19.2) 4576 (6.8%)
Hypertension† 33 470 (52.2) 2781 (4.2%)
Average daily alcohol consumption (g) 3.0 (0.0 to 12.0) 11 777 (17.6%)
History of MI or stroke 3625 (5.4) 62 (0.1%)
C reactive protein (mg/L) 1.4 (0.7 to 2.9) 34 058 (50.9%)‡
Nt- proBNP (pg/mL) 52 (27 to 96) 40 903 (61.1%)§
log10 (Nt- proBNP (pg/mL)) 1.7 (1.4 to 2.0) 40 903 (61.1%)§
Creatinine (mg/dL) 0.8 (0.7 to 0.9) 34 065 (50.9%)¶
eGFR¶ 94.8 (84.0 to 103.5) 34 065 (50.9%)‡
*Mean of two measurements.
†Systolic blood pressure ≥140 mm Hg and/or taking antihypertensive drugs.
‡Missing by design in the Tromsø Study and partly in other studies than the 
1997 cohort of FINRISK (online supplemental tables S2 and S4).
§Missing by design in DAN- MONICA and the Tromsø Study, and partly in 
other studies except the 1997 cohort of FINRISK (online supplemental tables 
S1, S2 and S4).
¶Using the Chronic Kidney Disease Epidemiology Collaboration formula with 
creatinine.
BMI, body mass index; eGFR, estimated glomerular filtration rate; MI, 
myocardial infarction; MORGAM, MOnica Risk, Genetics, Archiving and 
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Table 4 shows risk of AF attributed to each modifiable 
risk factor in age strata (ie, PAF for 5- year incident AF). 
Among lifestyle risk factors, BMI contributed to 8%–18% 
of the AF risk at ages <70, but at older ages, the relative 
attribution to BMI was low and non- significant (4.0%, 
95% CI −1.31 to 9.20). Hypertension showed significant 
PAFs of 20% only at ages≥60 years, whereas diabetes 
showed a significant PAF only at ages≥70 years (6.0%, 
95% CI 2.21 to 9.68). A history of stroke or MI contrib-
uted significantly to AF risk in all age groups with PAFs 
increasing gradually from 5% to 10%. Smoking and 
alcohol intake showed modest and non- significant PAFs. 
In general, 30%–40% of the AF risk could be attributed 
to BMI, hypertension and a history of stroke or MI.
During the follow- up, 8.4% (n=5622) participants died, 
whereas 3.1% (n=2055) were diagnosed with stroke. New- 
onset AF was associated with a 1.8- fold to 2.6- fold increase 
in risk of death at ages ≥60 years (multivariable- adjusted 
p≤0.001, figure 2) and with a twofold risk of stroke at ages 
≥70 years (HR 2.02, 95% CI 1.46 to 2.79, figure 2).
DISCUSSION
In this large, community- based cohort, risk of new- onset 
AF was associated with several lifestyle- related risk factors 
such as overweight, hypertension, high alcohol consump-
tion and a history of MI or stroke. In all age groups, AF 
burden was largely attributable to BMI, hypertension, 
and previous stroke or MI, together explaining 30%–40% 
of the AF risk. However, their PAF varied with age, as we 
found a substantial AF burden attributed to BMI at ages 
40–69 years, but low PAF for BMI among the oldest. PAF 
for hypertension was highest and significant only at ages 
≥60 years, whereas PAF for previous MI or stroke showed 
Table 2 Risk factor distribution by age groups at baseline









BMI (kg/m2) 25.5 (23.1 to 28.4) 26.8 (24.2 to 29.8) 27.5 (24.8 to 30.7) 27.0 (24.3 to 30.1)
  <30 20 806 (84.0) 16 418 (75.8) 9414 (70.6) 4949 (73.8)
  ≥30 3951 (16.0) 5250 (24.2) 3926 (29.4) 1757 (26.2)
Systolic blood pressure (mm Hg)* 129 (119 to 141) 138 (125 to 152) 145 (132 to 160) 154 (140 to 170)
  <140 18 097 (73.1) 11 658 (53.8) 5277 (39.6) 1667 (24.8)
  ≥140 6656 (26.9) 10 023 (46.2) 8058 (60.4) 5056 (75.2)
Diabetes 539 (2.2) 1115 (5.1) 1196 (8.9) 676 (10.0)
Daily smoker 7802 (31.4) 5871 (27.0) 2628 (19.7) 1004 (15.0)
Taking antihypertensive drugs 1608 (7.0) 3958 (19.6) 3989 (31.3) 2422 (36.9)
Hypertension† 7389 (31.6) 11 423 (54.7) 9150 (69.5) 5508 (82.2)
Total serum cholesterol (mmol/L) 5.7 (5.0 to 6.5) 6.1 (5.3 to 6.9) 6.1 (5.3 to 6.9) 6.1 (5.3 to 7.1)
  ≤6.5 18 830 (76.3) 14 074 (65.1) 8556 (64.4) 4162 (62.3)
  >6.5 5859 (23.7) 7558 (34.9) 4721 (35.6) 2522 (37.7)
Average daily alcohol consumption (g) 3.0 (0.0 to 12.0) 3.0 (0.0 to 12.0) 2.0 (0.0 to 11.0) 2.0 (0.0 to 12.0)
History of MI or stroke 285 (1.1) 1024 (4.7) 1255 (9.3) 1061 (15.7)
eGFR‡ 104.7 (93.9 to 109.3) 96.9 (85.5 to 101.9) 89.8 (78.2 to 95.0) 81.9 (69.9 to 87.9)
C reactive protein (mg/L) 1.0 (0.5 to 2.2) 1.4 (0.7 to 3.0) 1.7 (0.9 to 3.6) 1.9 (1.0 to 3.9)
Nt- proBNP (pg/mL) 35.9 (19.8 to 62.3) 44.9 (25.1 to 78.9) 70.8 (40.2 to 125.5) 126.6 (70.8 to 228.4)
log10 (Nt -proBNP (pg/mL)) 1.6 (1.3 to 1.8) 1.7 (1.4 to 1.9) 1.9 (1.6 to 2.1) 2.1 (1.8 to 2.4)
Continuous variables are presented as median and IQR (25th and 75th percentile), binary variables as absolute and relative frequencies.
*Mean of two measurements.
†Systolic blood pressure ≥140 mm Hg and/or taking antihypertensive drugs.
‡Using the Chronic Kidney Disease Epidemiology Collaboration formula with creatinine.
BMI, body mass index; eGFR, estimated glomerular filtration rate; MI, myocardial infarction; Nt- pro- BN, N- terminal- pro B- type natriuretic peptide.
Figure 1 Risk of AF by age groups, presented as HR with 
95% CI. HRs were presented on a log scale with base 2, 
adjusted for sex, BMI, SBP, total serum cholesterol, daily 
smoking, history of diabetes, antihypertensive drugs, daily 
alcohol consumption, and study site. AF, atrial fibrillation; 
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a slight increase with age. Finally, we found that newly 
diagnosed AF was associated with a twofold increase in 
risk of death and stroke but only at older ages.
AF incidence, risk factors and attributable risks
We observed a substantial increase in AF incidence with 
age that is comparable to age- specific incidence rates in 
the Rotterdam Study11 and the Reykjavik study9 but some-
what lower than the Framingham Study incidence rates.10 
The increasing incidence of AF9–11 highlights the impor-
tance of modifiable risk factors,27 28 which can be targeted 
and may contribute to prevention or deferral of AF onset. 
In the present study, several modifiable risk factors such 
as BMI, previous MI or stroke, hypertension and alcohol 
consumption were associated with increased risk of AF, 
the first two consistently in all age groups. These observa-
tions are largely in agreement with a study of 10 million 
individuals in a national Korean health insurance data-
base,29 which showed that modifiable risk factors such as 
BMI, high alcohol intake, and hypertension increased 
the risk of AF in all age groups.
Our study extends previous research by addressing the 
proportion of incident AF that could be attributed to a 
Table 3 Multivariable- adjusted HR for AF by age groups









BMI (per 5 kg/m2 increase) 1.41 (1.18 to 1.68,<0.001) 1.37 (1.23 to 1.53,<0.001) 1.37 (1.25 to 1.50,<0.001) 1.17 (1.06 to 1.29, 0.001)*
Diabetes 0.57 (0.18 to 1.80, 0.337) 1.48 (1.04 to 2.09, 0.029) 1.27 (0.96 to 1.66, 0.090) 1.59 (1.23 to 2.06,<0.001)
Daily smoker 1.13 (0.79 to 1.63, 0.501) 1.14 (0.89 to 1.45, 0.305) 1.16 (0.92 to 1.46, 0.220) 1.00 (0.78 to 1.27, 0.988)
Hypertension† 1.40 (0.98 to 2.00, 0.068) 1.19 (0.94 to 1.51, 0.138) 1.32 (1.07 to 1.64, 0.011) 1.29 (1.02 to 1.63, 0.035)
Total serum cholesterol (per mmol/L 
increase)
0.91 (0.78 to 1.06, 0.242) 0.91 (0.83 to 0.99, 0.039) 0.89 (0.83 to 0.97, 0.004) 0.96 (0.89 to 1.03, 0.283)
Average daily alcohol consumption 
(per 20 g increase)
1.18 (1.02 to 1.36, 0.025) 1.17 (1.05 to 1.30, 0.005) 1.13 (1.00 to 1.28, 0.049) 0.92 (0.79 to 1.08, 0.327)‡
History of MI or stroke 4.60 (2.56 to 8.27,<0.001)§ 1.93 (1.40 to 2.67,<0.001) 1.68 (1.32 to 2.13,<0.001) 1.57 (1.27 to 1.94,<0.001)
eGFR¶ 1.07 (0.90 to 1.26, 0.430) 0.93 (0.84 to 1.03, 0.193) 1.00 (0.92 to 1.09, 0.984) 0.88 (0.81 to 0.96, 0.005)
C reactive protein (mg/L) 0.94 (0.83 to 1.06, 0.295) 1.00 (0.97 to 1.03, 0.960) 1.01 (0.99 to 1.02, 0.245) 1.01 (0.99 to 1.02, 0.348)
Nt- pro- BNP (per 10- fold increase) 5.51 (2.70 to 11.24,<0.001) 4.80 (3.29 to 6.98,<0.001) 5.46 (4.08 to 7.31,<0.001) 7.58 (5.62–10.24,<0.001)
Values are HR (95% CI, p value).
Adjusted for age, sex, BMI, total serum cholesterol, daily smoking, diabetes, hypertension, daily alcohol consumption and study site.
*P≤0.033 for difference between ages ≥70, and 50–59 and 60–69, respectively.
†Systolic blood pressure ≥140 mm Hg and/or taking antihypertensive drugs.
‡p≤0.047 for difference between ages ≥70 and the other age groups.
§P≤0.011 for difference between ages 40–49 and the other age groups.
¶Using the Chronic Kidney Disease Epidemiology Collaboration formula with creatinine.
AF, atrial fibrillation; BMI, body mass index; eGFR, estimated glomerular filtration rate; MI, myocardial infarction; Nt- proBN, N- terminal- pro B- type 
natriuretic peptide.
Table 4 Multivariable- adjusted population attributable fraction for AF by age groups









BMI* 8.00 (0.43 to 15.56) 15.32 (7.74 to 22.90) 18.55 (12.18 to 24.92)† 3.95 (−1.31 to 9.20)
Diabetes −2.19 (−7.39 to 3.01) 3.39 (−0.12 to 6.91) 2.88 (−0.67 to 6.42) 5.95 (2.21 to 9.68)
Daily smoker 2.32 (−5.64 to 10.28) 2.95 (−2.60 to 8.50) 2.57 (−1.35 to 6.48) 0.08 (−2.49 to 2.66)
Hypertension‡ 15.03 (−1.74 to 31.79) 10.33 (−2.86 to 23.51) 19.83 (6.97 to 32.70) 20.03 (3.82 to 36.25)
Total serum cholesterol§ −5.54 (−12.25 to 1.17) −8.94 (−15.63 to −2.25) −4.93 (−11.04 to 1.17) −2.98 (−8.97 to 3.00)
Average daily alcohol consumption¶ 6.75 (−0.89 to 14.39) 1.84 (−3.33 to 7.00) 3.41 (0.12 to 6.70) −2.39 (−5.41 to 0.63)
History of MI or stroke 4.49 (0.28 to 8.69) 6.54 (1.62 to 11.46) 7.34 (3.63 to 11.04) 9.88 (5.89 to 13.87)
Adjusted for age, sex, BMI, total serum cholesterol, daily smoking, diabetes, hypertension, daily alcohol consumption and study site.
*Reference category ≤30 kg/m2.
†Significantly different from age ≥70, p=0.002; all other between- group p>0.008.
‡Systolic blood pressure ≥140 mm Hg and/or taking antihypertensive drugs.
§Reference category ≤6.5 mmol/L.
¶Reference category <20 g for women,<40 g for men.
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risk factor at different ages. The proportion of AF risk 
attributed to BMI increased with age up to 70 years, with 
PAFs of 15%–18% which is comparable to the Atheroscle-
rosis Risk in Communities Study.8 At ages ≥70 years, PAF 
for BMI was low and not statistically significant, suggesting 
that at older ages new- onset AF is primarily attributed to 
factors other than BMI. The risk of AF attributed to hyper-
tension was high at all ages with the highest attributable 
fractions in participants ≥60 years, accounting for 20% 
of incident AF, which is similar to results reported from 
other studies.8 30 As expected at population level, the risk 
of AF attributed to previous MI or stroke increased with 
age, possibly due to the observed age- related increase in 
prevalence of MI and stroke. Our findings underline the 
need to prevent and monitor cardiovascular risk factors 
and disease onset at an early age in order to prevent or 
postpone AF and its sequelae.
Stroke and mortality after AF onset
Increased risks of stroke and mortality are well- known 
complications of AF.17 However, age- specific compli-
cations of AF are scarcely examined in large cohorts, 
although clinically, older age is a strong predictor of 
stroke in AF patients,31 manifested through integration in 
stroke prediction scores such as the ABC and CHA2DS2- 
VASc scores. In the present study, AF significantly 
predicted stroke only at ages ≥70 years, with a twofold 
increase in stroke risk. This is in contrast to a large Danish 
study, showing increased stroke risks due to AF of 1.6–2.0 
as early as the age of 50 years.32 Wolf et al2 found no differ-
ences in stroke risk due to AF with advancing age in the 
Framingham Study, although the proportion of strokes 
attributed to AF increased from 1.5% at ages 50–59 years 
to 23% at ages 80–89.2 Oral anticoagulation or alternative 
ways of stroke risk reduction need to be addressed thor-
oughly in all age groups, but with an emphasis in older 
patients.
We found that AF significantly increased the risk of death 
at ages ≥60 years, with a 1.8- fold to 2.6- fold increase in 
mortality in AF patients. A large cohort study of Japanese 
men and women showed similar mortality rates in relation 
to AF in the age range 40–69 years.33 However, AF itself 
accounts for a comparatively small fraction of deaths world-
wide,1 since the mortality risk in AF patients is attributed to 
other causes such as heart failure and stroke.34
Limitations and strengths
The included cohorts originate from population- based 
studies to which entire birth cohorts or random samples 
were invited; however, we cannot rule out selection bias 
due to selective participation. Previous studies indicate 
that non- participants may have lower socioeconomic 
status and higher prevalences of non- communicable 
diseases.35 Participation among the oldest old was lower, 
which prompted us to merge data on participants >70 
years, limiting knowledge among this specific group. We 
did not stratify by sex, as sex differences in AF risk factors 
were addressed previously in a similar cohort.17
Furthermore, misclassification and lack of valid data 
on potential residual confounders such as physical 
activity may lead to biased estimates. Combining data 
from heterogeneous cohorts may introduce misclassifi-
cation, although we attempted to improve the goodness- 
of- fit of the Cox models by adjusting for study cohort. 
Data on risk factors were available only at baseline, and 
procedures and thresholds may have changed during 
follow- up. Information on AF is derived from hospital 
discharge records and individuals with paroxysmal AF 
and silent AF are probably underrepresented, which may 
weaken the associations, although validation studies show 
high positive and negative predictive values for AF diag-
noses from diagnosis registers.36 37
Strengths of this study include the prospective design 
with long- term follow- up, rigorously harmonised risk 
factors and endpoints and a large sample size, repre-
senting Europe from North to South.
CONCLUSIONS
In this cohort of adult and elderly European men and 
women, incidence of AF increased significantly with age. 
High BMI, hypertension, high alcohol consumption and 
previous stroke or MI predicted risk of AF across age groups. 
In particular, the PAF of BMI was substantial at ages 40–69 
years, and a large proportion of the AF risk was attributed 
to hypertension, with an age- related increase. Therefore, 
preventive measures should target risk factors rigorously 
from middle- aged to older individuals. Newly diagnosed 
AF was associated with a high risk of stroke and mortality 
in risk factor adjusted analyses, in particular at older age. 
Our study, thus, emphasises the potential role of risk factor 
control for prevention and adequate patient management 
after AF diagnosis in the older age groups, including the 
oldest old.
Figure 2 Risk of stroke and mortality according to 
new- onset AF versus no AF, presented as HR with 
95% CI. HRs were adjusted for age, sex, BMI, SBP, total 
serum cholesterol, daily smoking, history of diabetes, 
antihypertensive drugs, daily alcohol consumption, and study 
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